These insights suggest potential avenues for targeted therapies in AML that could exploit the SPAG5-MDM2 interaction to modulate the pathway favourably, enhancing the apoptotic response in AML cells and potentially improving patient outcomes. Here, MDM2 is linked to acute myeloid leukemia.